DOP2010000254A - Inhibidores del receptor de quimioquinas cxcr3 - Google Patents

Inhibidores del receptor de quimioquinas cxcr3

Info

Publication number
DOP2010000254A
DOP2010000254A DO2010000254A DO2010000254A DOP2010000254A DO P2010000254 A DOP2010000254 A DO P2010000254A DO 2010000254 A DO2010000254 A DO 2010000254A DO 2010000254 A DO2010000254 A DO 2010000254A DO P2010000254 A DOP2010000254 A DO P2010000254A
Authority
DO
Dominican Republic
Prior art keywords
cxcr3
chemiokin
inhibitors
receiver
benzosulfonamide
Prior art date
Application number
DO2010000254A
Other languages
English (en)
Spanish (es)
Inventor
David S Thorpe
Martin Smrcina
Dagmar D Cabel
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of DOP2010000254A publication Critical patent/DOP2010000254A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
DO2010000254A 2008-02-19 2010-08-18 Inhibidores del receptor de quimioquinas cxcr3 DOP2010000254A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2973808P 2008-02-19 2008-02-19

Publications (1)

Publication Number Publication Date
DOP2010000254A true DOP2010000254A (es) 2010-08-31

Family

ID=40527535

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2010000254A DOP2010000254A (es) 2008-02-19 2010-08-18 Inhibidores del receptor de quimioquinas cxcr3

Country Status (25)

Country Link
US (1) US8268828B2 (enExample)
EP (1) EP2262784B1 (enExample)
JP (1) JP2011512412A (enExample)
KR (1) KR20100123835A (enExample)
CN (1) CN102007108A (enExample)
AR (1) AR070430A1 (enExample)
AU (1) AU2009215643A1 (enExample)
BR (1) BRPI0908815A2 (enExample)
CA (1) CA2715557A1 (enExample)
CL (1) CL2009000368A1 (enExample)
CO (1) CO6241113A2 (enExample)
CR (1) CR11604A (enExample)
DO (1) DOP2010000254A (enExample)
EC (1) ECSP10010409A (enExample)
IL (1) IL207597A0 (enExample)
MA (1) MA32191B1 (enExample)
MX (1) MX2010008397A (enExample)
NI (1) NI201000132A (enExample)
NZ (1) NZ587380A (enExample)
PE (1) PE20091576A1 (enExample)
RU (1) RU2010138577A (enExample)
SV (1) SV2010003648A (enExample)
TW (1) TW200948791A (enExample)
WO (1) WO2009105435A1 (enExample)
ZA (1) ZA201005314B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091576A1 (es) 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
EP2424840B1 (en) 2009-04-27 2014-08-06 Boehringer Ingelheim International GmbH Cxcr3 receptor antagonists
WO2011084985A1 (en) * 2010-01-07 2011-07-14 Boehringer Ingelheim International Gmbh Cxcr3 receptor antagonists
KR101251788B1 (ko) 2010-12-06 2013-04-08 기아자동차주식회사 차량 연비 정보 단말표시 시스템 및 그 방법
ES2649995T3 (es) 2011-07-18 2018-01-16 Merck Patent Gmbh Benzamidas
EP2601950A1 (en) 2011-12-06 2013-06-12 Sanofi Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists
WO2013106409A1 (en) 2012-01-10 2013-07-18 Merck Patent Gmbh Benzamide derivatives as modulators of the follicle stimulating hormone
CN104093715B (zh) 2012-02-02 2017-04-26 埃科特莱茵药品有限公司 4‑(苯并咪唑‑2‑基)‑噻唑化合物及相关氮杂衍生物
EP2666769A1 (en) 2012-05-23 2013-11-27 Sanofi Substituted B-amino acid derivatives as CXCR3 receptor antagonist
MX363432B (es) 2013-07-22 2019-03-22 Idorsia Pharmaceuticals Ltd Derivados 1-(piperazin-1-il)-2-([1,2,4]triazol-1-il)-etanona.
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
SG10201901192TA (en) * 2014-09-10 2019-03-28 Epizyme Inc Smyd inhibitors
EA032927B1 (ru) 2015-01-15 2019-08-30 Идорсия Фармасьютиклз Лтд Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
FI3600312T3 (fi) * 2017-03-26 2023-07-25 Takeda Pharmaceuticals Co Piperidinyyli- ja piperatsinyylisubstituoituja heteroaromaattisia karboksamideja gpr6:n modulaattoreina
CN115974766B (zh) * 2023-01-04 2025-05-16 中国药科大学 N-苄基-3-苯基酰胺类衍生物、包含其的药物组合物及其应用
CN116410159B (zh) * 2023-06-09 2023-08-22 济南国鼎医药科技有限公司 一种恩曲替尼中间体的制备方法及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719660A (en) 1969-06-13 1973-03-06 Takeda Chemical Industries Ltd 2-furfurylthioinosine-5'-phosphate compounds
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US6124319A (en) 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
US6469002B1 (en) 2001-04-19 2002-10-22 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
GB0203994D0 (en) 2002-02-20 2002-04-03 Celltech R&D Ltd Chemical compounds
US20050272936A1 (en) 2002-06-03 2005-12-08 Axten Jeffrey M Imidazolium cxcr3 inhibitors
US6734659B1 (en) 2002-06-13 2004-05-11 Mykrolis Corporation Electronic interface for use with dual electrode capacitance diaphragm gauges
EP1853587B1 (en) * 2005-02-16 2011-08-03 Schering Corporation Novel heterocyclic substituted pyridine or phenyl compounds with cxcr3 antagonist activity
WO2006088919A2 (en) 2005-02-16 2006-08-24 Schering Corporation Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
KR20070107060A (ko) 2005-02-16 2007-11-06 쉐링 코포레이션 Cxcr3 길항제 활성을 갖는 피라지닐 치환된피페라진-피페리딘
US20080312215A1 (en) * 2005-06-28 2008-12-18 Pharmacopeia Drug Discovery, Inc. Substituted [1,4]-diazepanes as CXCR3 antagonists and their use in the treatment of inflammatory disorders
ES2382163T3 (es) 2005-10-11 2012-06-05 Schering Corporation Compuestos heterocíclicos sustituidos con actividad antagonista de CXCR3
WO2007064553A2 (en) 2005-11-29 2007-06-07 Merck & Co., Inc. Thiazole derivatives as cxcr3 receptor modulators
AU2007227425A1 (en) 2006-03-21 2007-09-27 Pharmacopeia, Inc. Heterocyclic substituted pyridine compounds with CXCR3 antagonist activity
CN101516869A (zh) 2006-07-14 2009-08-26 先灵公司 具有cxcr3拮抗剂活性的杂环取代的哌嗪化合物
PE20091576A1 (es) 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3

Also Published As

Publication number Publication date
AU2009215643A1 (en) 2009-08-27
BRPI0908815A2 (pt) 2019-09-24
WO2009105435A1 (en) 2009-08-27
CA2715557A1 (en) 2009-08-27
ZA201005314B (en) 2011-03-30
CO6241113A2 (es) 2011-01-20
TW200948791A (en) 2009-12-01
EP2262784B1 (en) 2014-04-16
SV2010003648A (es) 2011-01-31
US8268828B2 (en) 2012-09-18
PE20091576A1 (es) 2009-11-05
EP2262784A1 (en) 2010-12-22
ECSP10010409A (es) 2010-09-30
CL2009000368A1 (es) 2009-06-26
MA32191B1 (fr) 2011-04-01
NI201000132A (es) 2011-03-16
KR20100123835A (ko) 2010-11-25
NZ587380A (en) 2011-09-30
CR11604A (es) 2010-10-05
MX2010008397A (es) 2010-08-23
CN102007108A (zh) 2011-04-06
AR070430A1 (es) 2010-04-07
RU2010138577A (ru) 2012-03-27
IL207597A0 (en) 2010-12-30
JP2011512412A (ja) 2011-04-21
US20100305088A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
DOP2010000254A (es) Inhibidores del receptor de quimioquinas cxcr3
CY1122778T1 (el) Μετεγχειρητικοι φραγμοι προσκολλησης
CR20110257A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
CR20110103A (es) Heteroarilos sustituidos
CU20140025A7 (es) Pirimidinas anilladas sustituidas
GT201400191A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
CY1119030T1 (el) Χρηση των δεσμων σιγμα στον πονο του καρκινου των οστων
HN2012000973A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
MA32562B1 (fr) Composes organiques pour la cicatrisation de lesion
EA201200550A1 (ru) Фармацевтические композиции, включающие bi-1356 и метформин
BRPI0813966A8 (pt) Usos de mdl-1
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
CL2009000171A1 (es) Compuestos derivados de 1-oxa-3-azaespiro, antagonistas del receptor y5 de neuropeptido y (npy); composicion farmaceutica que comprende dicho compuesto; y uso para el tratamiento de trastornos de la alimentacion, trastornos de la bebida, obesidad y depresion.
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
BRPI0917017A2 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
NI201000035A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
CR20110202A (es) Antagonistas de la via hedgehog de ftalazina disustituida
UY32214A (es) Agonistas del receptor s1p para el tratamiento de malaria cerebral
CR20110368A (es) Compuestos de quinazolina sustituidos
PA8782301A1 (es) Tratamiento de leucemia resistente al imatinte
CR10111A (es) Modulares de canabinoide de 5-heteroaril-1-fenil-pirazol sustituido
UA107346C2 (en) Use of nifuratel to treat infections caused by atopobium species
UY31717A1 (es) (pirazolilcarbonil) imidazolidinonas sustituidas y su uso